Biotech Values

[kris_kade]

Bernstein said it had learned that Novartis' generic Sandoz division was setting prices and soliciting pre-orders from U.S. purchasers for its generic form of Lovenox, or enoxaparin.

Agree on NVS not issuing any such statements per se...however could it be that Bernstien conveyed a hightened sense of such 'activity' which market seems to be inferring as approval being imminent ?

It's bit intriguing that Bernstien could or would not comment on MNTA getting the sole approval or not, assuming his information is more than just stemming from inference.